In addition, annual estimates of RSV-associated ICU admissions ranged from 24,400 to 34,900 for the 2016-2017 and 2017-2018 ...

The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

especially in indoor spaces These respiratory droplets and aerosols are created when an infected person: COVID-19 can also spread by touching something that has the virus on it, then touching your ...

In August 2023, BD received FDA clearance for its BD Respiratory Viral Panel (RVP) for the BD MAXTM System. This innovative single molecular diagnostic combination test swiftly identified and ...

The North Bay Parry Sound District Health Unit announced the availability of a new preventive medication for Respiratory Syncytial Virus for newborns and eligible infants up to 24 months of age. The ...

To illustrate the applicability of our analytic technique, we employ our method to infer the synaptic conductance profiles in identified rhythmically active interneurons within key microcircuits of ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

On Tuesday, the FDA approved Pfizer Inc’s (NYSE:PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, to prevent lower respiratory tract ...

The Abrysvo vaccine protects infants – who are highly susceptible to respiratory syncytial virus (RSV) – against lower respiratory tract disease caused by the contagious virus, until they are ...

has been approved for the prevention of lower respiratory tract diseases, such as pneumonia and bronchitis, caused by respiratory syncytial virus, or RSV, in people between the ages of 18 and 59.